Credit Suisse (SIX:CSGN) analyst Evan Seigerman maintained a Hold rating on Incyte (NASDAQ:INCY) Corp on Friday, setting a price target of $97, which is approximately 14.02% above the present share price of $85.07.
Seigerman expects Incyte Corp to post earnings per share (EPS) of $1.33 for the third quarter of 2020.
The current consensus among 14 TipRanks analysts is for a Moderate Buy rating of shares in Incyte, with an average price target of $103.73.
The analysts price targets range from a high of $124 to a low of $87.
In its latest earnings report, released on 06/30/2020, the company reported a quarterly revenue of $688.04 million and a net profit of $236.79 million. The company's market cap is $18.6 billion.
According to TipRanks.com, Credit Suisse analyst Evan Seigerman is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 16.0% and a 57.41% success rate.
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.